Wedbush stays positive on Viridian shares after Acelyrin data

Wedbush is not changing the firm’s positive bias on Viridian Therapeutics (VRDN) after its competitor Acelyrin (SLRN) hosted an investor event to disclose lonigutamab Phase 2 data and plans for Phase 3 studies. While Wedbush wonders about the feasibility of the lonigutamab timeline, it sees Viridian as holding a more competitive program in thyroid eye disease with subcutaneously administered VRDN-003, which is in Phase 3 studies. The company remains on track to report Phase 3 VRDN-003 results in the second half of 2026, the analyst tells investors in a research note. Wedbush continues to like the current entry point, saying Viridian’s cash offers a runway into the second half of 2027, or well past a potential veligrotug commercial launch and completion of VRDN-003 Phase 3 studies. It keeps an Outperform rating on the shares with a $48 price target.